|

EIK1005 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Eikon Therapeutics1

Indications

  • Mismatch Repair Deficient or MSI-High Solid Tumors1
  • MSI-H/dMMR Colorectal Cancer1
  • MSI-H or dMMR Advanced Solid Tumors1
  • MSI-H/dMMR Gastroesophageal-junction Cancer1
  • MSI-H/dMMR Gastric Cancer1

Morristown, New Jersey1 trial

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Morristown Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.